Please assess the completion status of the following clinical trial:

Trial Title: Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patients with AML aged from 18 to 65 years~* Eastern Cooperative Oncology Group (ECOG) performance \< 2~* High risk group for relapse~  1. Complete remission (CR) 1 with unfavorable prognostic factor; presenting white blood cell \> 100,000/microliter or prior myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) or MDS/MPN or cytogenetics \& molecular features (intermediate and adverse)~ 2. CR2 or CR3 at transplantation~* No HLA-matched sibling and unrelated donor (HLA-A, -B, -C, and -DRB1)~* Acceptable organ function defined as serum creatinine \< 2 mg/dl, unless considered due to leukemia and serum bilirubin \< 3 mg/dl, unless considered due to leukemia~* Written informed consent form~Exclusion Criteria~* Active uncontrolled infections~* Corrected pulmonary diffusion capacity of \<40%~* Cardiac ejection fraction of \<35%~* ECOG performance status :2, 3, 4~* Active central nervous system involvement of disease~* Serological evidence of infection with HIV~* Pregnancy or breastfeeding~* Patient who are not suitable for the trial in accordance with principal investigator's decision

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplants from 8/8-matched unrelated (Type: ACTIVE_COMPARATOR): Participants will receive transplants from 8/8-matched unrelated donors using myeloablative or reduced-intensity conditioning according to age or comorbidity.
- Transplants from family-mismatched/haploidentical donors (Type: EXPERIMENTAL): Participants will receive FMT using a reduced intensity conditioning regimens.

Based on this trial design, predict the completion outcome and termination type (if applicable).